AU2018277523B2 - 5-5 fused rings as C5a inhibitors - Google Patents

5-5 fused rings as C5a inhibitors Download PDF

Info

Publication number
AU2018277523B2
AU2018277523B2 AU2018277523A AU2018277523A AU2018277523B2 AU 2018277523 B2 AU2018277523 B2 AU 2018277523B2 AU 2018277523 A AU2018277523 A AU 2018277523A AU 2018277523 A AU2018277523 A AU 2018277523A AU 2018277523 B2 AU2018277523 B2 AU 2018277523B2
Authority
AU
Australia
Prior art keywords
compound
alkyl
disease
mmol
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018277523A
Other languages
English (en)
Other versions
AU2018277523A1 (en
Inventor
Pingchen Fan
Christopher W. Lange
Rebecca M. LUI
Viengkham Malathong
Venkat Reddy Mali
Sreenivas Punna
Yibin Zeng
Penglie Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemocentryx Inc
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of AU2018277523A1 publication Critical patent/AU2018277523A1/en
Application granted granted Critical
Publication of AU2018277523B2 publication Critical patent/AU2018277523B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Liquid Crystal Substances (AREA)
  • Glass Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Insulating Materials (AREA)
AU2018277523A 2017-05-31 2018-05-29 5-5 fused rings as C5a inhibitors Active AU2018277523B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762513025P 2017-05-31 2017-05-31
US62/513,025 2017-05-31
PCT/US2018/034908 WO2018222601A1 (en) 2017-05-31 2018-05-29 5-5 FUSED RINGS AS C5a INHIBITORS

Publications (2)

Publication Number Publication Date
AU2018277523A1 AU2018277523A1 (en) 2019-12-05
AU2018277523B2 true AU2018277523B2 (en) 2022-06-23

Family

ID=64455572

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018277523A Active AU2018277523B2 (en) 2017-05-31 2018-05-29 5-5 fused rings as C5a inhibitors

Country Status (16)

Country Link
US (2) US10683294B2 (enExample)
EP (1) EP3630774B1 (enExample)
JP (1) JP7141129B2 (enExample)
KR (1) KR102586710B1 (enExample)
CN (1) CN111032658B (enExample)
AR (1) AR111841A1 (enExample)
AU (1) AU2018277523B2 (enExample)
CA (1) CA3064025A1 (enExample)
ES (1) ES2934507T3 (enExample)
IL (1) IL270842B2 (enExample)
MA (1) MA48800A (enExample)
MX (1) MX391392B (enExample)
NZ (1) NZ759295A (enExample)
TW (1) TWI813570B (enExample)
WO (1) WO2018222601A1 (enExample)
ZA (1) ZA201907755B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102638253B1 (ko) 2017-05-31 2024-02-16 케모센트릭스, 인크. C5a 억제제로서의 6-5 융합 고리
JP7141129B2 (ja) 2017-05-31 2022-09-22 ケモセントリックス，インコーポレイティド Ｃ５ａ阻害剤としての５－５融合環
MA51327A (fr) 2017-12-22 2021-05-26 Chemocentryx Inc Composés cycliques fusionnés en 5,5 à substitution diaryle, utilisés en tant qu'inhibiteurs du c5ar
MX2020006459A (es) 2017-12-22 2020-11-06 Chemocentryx Inc Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar.
ES2993034T3 (en) * 2018-04-02 2024-12-20 Chemocentryx Inc Prodrugs of fused-bicyclic c5ar antagonists
KR102890201B1 (ko) 2019-07-10 2025-11-24 케모센트릭스, 인크. Pd-l1 억제제로서의 인단
CN112300169B (zh) * 2019-07-26 2022-03-04 上海美迪西生物医药股份有限公司 吡咯并吡唑类衍生物、其制备方法及其在医药上的应用
ES3068390T3 (en) 2019-10-16 2026-05-29 Chemocentryx Inc Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases
AU2020368392B2 (en) 2019-10-16 2026-01-08 Chemocentryx, Inc. Heteroaryl-biphenyl amines for the treatment of PD-L1 diseases
US12668593B2 (en) 2020-09-28 2026-06-30 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Pyrazole compound and preparation method therefor and use thereof
CA3192880A1 (en) 2020-10-28 2022-05-05 Chemocentryx, Inc. Methods of treating hidradenitis suppurativa

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080267887A1 (en) * 2004-10-05 2008-10-30 Neurogen Corporation Pyrrolo-Pyridine, Pyrrolo-Pyrimidine and Related Heterocyclic Compounds
US20140051688A1 (en) * 2012-08-16 2014-02-20 Janssen Pharmaceutica Nv Pyrrolopyrazoles as n-type calcium channel blockers

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2416527C (en) 2000-08-10 2009-12-22 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
AU7622500A (en) 2000-09-29 2002-07-01 Neurogen Corp High affinity small molecule c5a receptor modulators
SE524438C2 (sv) 2000-10-05 2004-08-10 Magnus Georg Goertz Fjärrstyrt dörrelaterat låsarrangemang, första och andra datorpogramprodukt, bärande medium och ett datorlösbart medium
US7902179B2 (en) 2001-04-26 2011-03-08 Ajinomoto Co., Inc. Heterocyclic compounds
ITMI20012025A1 (it) 2001-09-28 2003-03-28 Dompe Spa Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono
WO2003082828A1 (en) 2002-03-28 2003-10-09 Neurogen Corporation Substituted tetrahydroisoquinolines as c5a receptor modulators
CA2479928A1 (en) 2002-03-28 2003-10-09 Neurogen Corporation Substituted biaryl amides as c5a receptor modulators
WO2003084524A1 (en) 2002-03-29 2003-10-16 Neurogen Corporation Combination therapy for the treatment of conditions with pathogenic inflammatory components
WO2004016592A1 (en) 2002-08-14 2004-02-26 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
US7169775B2 (en) 2002-08-21 2007-01-30 Neurogen Corporation Amino methyl imidazoles as C5a receptor modulators
AU2003291403A1 (en) 2002-11-08 2004-06-03 Neurogen Corporation 3-substituted-6-aryl pyridined as ligands of c5a receptors
US20040214856A1 (en) 2003-04-23 2004-10-28 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
AU2003902354A0 (en) 2003-05-15 2003-05-29 Harkin, Denis W. Treatment of haemorrhagic shock
US20060154917A1 (en) 2003-07-03 2006-07-13 Neurogen Corporation Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
US20070112015A1 (en) 2005-10-28 2007-05-17 Chemocentryx, Inc. Substituted dihydropyridines and methods of use
PE20110063A1 (es) 2008-06-20 2011-02-16 Genentech Inc DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK
JP5819730B2 (ja) 2008-12-22 2015-11-24 ケモセントリックス，インコーポレイティド Ｃ５ａＲアンタゴニスト
US20110275639A1 (en) 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
DK2585064T3 (en) 2010-06-24 2017-07-24 Chemocentryx Inc C5aR antagonists
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
CN103421006B (zh) 2013-08-18 2016-06-22 上海师范大学 2,3,5,7-四取代二氢吡唑并六氢吡啶衍生物及其制备方法和应用
GB201321746D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
SG11201808625QA (en) 2016-04-04 2018-10-30 Chemocentryx Inc SOLUBLE C5aR ANTAGONISTS
KR102638253B1 (ko) 2017-05-31 2024-02-16 케모센트릭스, 인크. C5a 억제제로서의 6-5 융합 고리
JP7141129B2 (ja) 2017-05-31 2022-09-22 ケモセントリックス，インコーポレイティド Ｃ５ａ阻害剤としての５－５融合環
MX2020006459A (es) 2017-12-22 2020-11-06 Chemocentryx Inc Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar.
MA51327A (fr) 2017-12-22 2021-05-26 Chemocentryx Inc Composés cycliques fusionnés en 5,5 à substitution diaryle, utilisés en tant qu'inhibiteurs du c5ar
ES2993034T3 (en) 2018-04-02 2024-12-20 Chemocentryx Inc Prodrugs of fused-bicyclic c5ar antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080267887A1 (en) * 2004-10-05 2008-10-30 Neurogen Corporation Pyrrolo-Pyridine, Pyrrolo-Pyrimidine and Related Heterocyclic Compounds
US20140051688A1 (en) * 2012-08-16 2014-02-20 Janssen Pharmaceutica Nv Pyrrolopyrazoles as n-type calcium channel blockers

Also Published As

Publication number Publication date
RU2019142985A (ru) 2021-06-30
MX2019014292A (es) 2022-04-07
JP2020522483A (ja) 2020-07-30
US10683294B2 (en) 2020-06-16
US20180346471A1 (en) 2018-12-06
MA48800A (fr) 2020-04-08
WO2018222601A1 (en) 2018-12-06
CN111032658B (zh) 2022-12-20
IL270842B2 (en) 2023-05-01
NZ759295A (en) 2026-03-27
RU2019142985A3 (enExample) 2021-09-03
EP3630774A4 (en) 2020-10-07
TWI813570B (zh) 2023-09-01
ES2934507T3 (es) 2023-02-22
KR20200013720A (ko) 2020-02-07
ZA201907755B (en) 2023-05-31
US20210009594A1 (en) 2021-01-14
IL270842A (en) 2020-01-30
JP7141129B2 (ja) 2022-09-22
AU2018277523A1 (en) 2019-12-05
KR102586710B1 (ko) 2023-10-10
AR111841A1 (es) 2019-08-21
EP3630774A1 (en) 2020-04-08
TW201902897A (zh) 2019-01-16
MX391392B (es) 2025-03-21
CN111032658A (zh) 2020-04-17
BR112019025230A2 (pt) 2020-06-16
IL270842B1 (en) 2023-01-01
EP3630774B1 (en) 2022-11-23
US11479553B2 (en) 2022-10-25
CA3064025A1 (en) 2018-12-06

Similar Documents

Publication Publication Date Title
US11773091B2 (en) 6-5 fused rings as C5a inhibitors
US11479553B2 (en) 5-5 fused rings as C5a inhibitors
AU2018388657C1 (en) Diaryl substituted 5,5-fused ring compounds as C5aR inhibitors
AU2018388655C1 (en) Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors
RU2780322C2 (ru) 5-5 КОНДЕНСИРОВАННЫЕ КОЛЬЦА КАК ИНГИБИТОРЫ С5а
HK40026719B (en) 5-5 fused rings as c5a inhibitors
HK40026719A (en) 5-5 fused rings as c5a inhibitors
HK40026727B (en) 6-5 fused rings as c5a inhibitors
HK40026727A (en) 6-5 fused rings as c5a inhibitors
BR112019025230B1 (pt) Anéis 5-5 fundidos como inibidores de c5a, seus usos e composição farmacêutica
HK40040271A (en) Diaryl substituted 6,5-fused ring compounds as c5ar inhibitors
HK40040271B (en) Diaryl substituted 6,5-fused ring compounds as c5ar inhibitors
BR112019025049B1 (pt) Compostos com anéis 6- 5 fundidos e composição farmacêutica que os compreende

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)